Skip to main content

Table 1 Demographic data

From: Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial

Patient ID Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Gender Female Female Male Male Male
Age 51 51 54 45 53
Weight 94 70 88 95 102
Initial vital signs (base)  
 RR breaths/min 22 28 42 36 28
 PR beats/min 71 92 89 66 92
 Sys BP, mmHg 141 103 124 139 138
 Dias BP, mmHg 76 71 89 90 97
 Temp > 37.3 (°C, baseline) 37 37.3 36.7 37.4 36.2
 SO2 (without oxygen mask) 87 70 79 80 89
Other  
 COVID type Sev Sev Sev Sev Sev
 Comorbidities Fatty liver disease HTN Damaged lung No Diabetes
 Interval between symptoms onset and admission (days) 6 10 11 13 4
 Interval between symptoms onset and first cell injection (days) 10 14 13 17 7
 Duration of hospitalization in ICU after cell injection 7 5 0 6 0
 Conventional therapy Hep/Dexa Hep/Dexa Hep/Dexa Hep/Dexa Hep/Dexa/Ataz
 RT-PCR at admission + + + + +
  1. Sev severe, HTN hypertension, Hep heparin, Dexa dexamethasone, Ataz atazanavir, RT-PCR reverse transcription polymerase chain reaction